OK, thank you for your contribution to the SurVaxM trial. I have very little opinion on it. What I just don’t understand is why such an intelligent and bright mind as Flipper would even suggest, and, after the last 10-Q, still speculate that NWBO and/or the MHRA would wait for the SurVaxM trial data to become completely available in order to compare it with the DCVax-L data. I mean, come on. From an MHRA review policy perspective, that's bonkers.
The MHRA wouldn’t delay a completed MAA review to wait for another data-relevant trial in a different product to finish, just to make a side-by-side comparison.
They review DCVax-L application as it has been submitted.
Market Data 
Markets 
AI
